Innovative radiation therapy for pancreatic cancer treatment
Project 2
This study is looking at a new way to treat pancreatic cancer using a special type of radiation called FLASH, which delivers high doses to tumors while protecting healthy tissue, and combines it with immunotherapy to boost the body's immune response, all aimed at improving treatment results for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11012039 on NIH RePORTER |
What this research studies
This research investigates a new approach called FLASH radiotherapy, which aims to treat pancreatic cancer by delivering ultra-high doses of radiation to tumors while minimizing damage to surrounding healthy tissues. The study explores the combination of FLASH radiotherapy with immunotherapy to enhance the immune response against both the treated tumor and any metastatic tumors. By using smart radiotherapy biomaterials, the project seeks to improve the delivery of immunotherapy, potentially leading to better patient outcomes. The research will also focus on establishing safety and effectiveness parameters for this new treatment method.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic cancer who may benefit from advanced radiation therapy options.
Not a fit: Patients with non-cancerous conditions or those who do not have pancreatic cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and quality of life for patients with pancreatic cancer.
How similar studies have performed: Other research has shown promising results with FLASH radiotherapy, indicating its potential as a novel treatment approach.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Ngwa, Wilfred — Johns Hopkins University
- Study coordinator: Ngwa, Wilfred
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.